Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Erdafitinib - Janssen Pharmaceuticals

Drug Profile

Erdafitinib - Janssen Pharmaceuticals

Alternative Names: BALVERSA; G-024; JNJ-42756493; JNJ-493

Latest Information Update: 10 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astex Therapeutics; Newcastle University
  • Developer Genentech; Janssen Pharmaceutica; Janssen Research & Development; Multiple Myeloma Research Consortium; National Cancer Institute (USA); University Health Network of Toronto; Vanderbilt-Ingram Cancer Center
  • Class Antineoplastics; Diamines; Pyrazoles; Quinoxalines; Small molecules
  • Mechanism of Action Fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Urogenital cancer
  • Phase II Cholangiocarcinoma; Gastric cancer; Multiple myeloma; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer
  • Phase I/II Liver cancer
  • Phase I Breast cancer; Lymphoma; Solid tumours

Most Recent Events

  • 21 Nov 2019 Janssen plans a phase II trial for Bladder cancer ((Late-stage disease, Second-line therapy or greater) in Australia, Belgium, Brazil, France, Germany, Poland, South Korea, Spain, Taiwan, United Kingdom, USA (PO) (NCT04172675)
  • 10 Sep 2019 Janssen Research & Development plans a phase II trial for Solid tumours (Late-stage disease, Second-line therapy or greater, Metastatic disease, In adolescents, In adults, In the elderly) in USA, Argentina, Australia, China, France, Italy, South Korea, Poland, Spain and United Kingdom (PO) in November 2019 (NCT04083976) (EudraCT2019-002113-19)
  • 31 May 2019 Efficacy and adverse events data from a phase II trial in Solid tumours presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top